NASDAQ:ATHE

Alterity Therapeutics - ATHE News Today

$3.91

+0.10 (+2.62%)

(As of 01/27/2023 12:00 AM ET)

Add

Compare

Today's Range: $3.80
▼
$3.97
50-Day Range: $2.95
▼
$4.29
52-Week Range: $2.90
▼
$10.50

Volume: 25,947 shs
Average Volume: 22,031 shs
Market Capitalization: $15.68 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $25.00

Institutional Ownership

Get Alterity Therapeutics News Delivered to You Automatically

ATHE Media Mentions By Week

ATHE Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

ATHE
News Sentiment
▼
0.62

0.72
▲
Average
Medical
News Sentiment

ATHE News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

ATHE Articles
This Week
▼
3

0
▲
ATHE Articles
Average Week

Source

Source	Headline
	Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in Italy for the Treatment of Individuals with Multiple System Atrophy finance.yahoo.com - January 25 at 8:28 AM
	Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in the United States for the Treatment of Individuals with Multiple System Atrophy finance.yahoo.com - January 9 at 3:15 PM
	Alterity Therapeutics to implement 1-for-10 reverse ADS split msn.com - January 7 at 10:58 AM
	Alterity Therapeutics Announces 1-for-10 Reverse ADS Split (consolidation) finance.yahoo.com - January 6 at 12:16 PM
	Alterity Therapeutics to Participate in the Sachs Associates 6th Annual Neuroscience Innovation Forum finance.yahoo.com - January 3 at 12:42 PM
	Alterity Therapeutics Announces Presentation of Data from the bioMUSE Natural History Study at the American Autonomic Society Annual Meeting finance.yahoo.com - November 7 at 3:14 PM
	Appendix 4C - Q1 FY23 Quarterly Cash Flow Report finance.yahoo.com - November 5 at 5:45 AM
	Alterity Therapeutics Announces Presentation of MRI Data from the bioMUSE Natural History Study at the American Neurological Association Annual Meeting finance.yahoo.com - October 26 at 11:50 AM
	Alterity Therapeutics Announces Presentation of Wearable Sensor Data from the bioMUSE Natural History Study at the International Congress of Parkinson's Disease and Movement Disorders finance.yahoo.com - September 26 at 9:47 AM
	Alterity Therapeutics Gets FDA Approval for IND Application for ATH434 marketwatch.com - September 20 at 5:06 PM
	Alterity Gets FDA Nod To Conduct Phase 2 Trial Of ATH434 In Multiple System Atrophy nasdaq.com - September 20 at 5:06 PM
	Alterity Therapeutics Receives U.S. FDA Approval for Investigational New Drug Application for ATH434 for the Treatment of Multiple System Atrophy finance.yahoo.com - September 20 at 5:06 PM
	Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial for the Treatment of Patients with Multiple System Atrophy in Europe finance.yahoo.com - August 25 at 7:33 AM
	Alterity Therapeutics: Appendix 4C - Q4 FY22 Quarterly Cash Flow Report finance.yahoo.com - July 22 at 11:02 AM
	Alterity wins Italian nod to study lead asset in Parkinsonian disorder seekingalpha.com - June 23 at 5:40 PM
	Life Sciences Investor Forum: Company Executives Present Live June 23rd finance.yahoo.com - June 21 at 8:41 AM
	Alterity Therapeutics to Present at the VirtualInvestorConferences.com Life Sciences Investor Forum finance.yahoo.com - June 20 at 7:39 AM
	Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial for the Treatment of Patients with Multiple System Atrophy finance.yahoo.com - June 2 at 10:54 AM
	Alterity gsts UK drug regulator nod for phase 2 study of ATH434 for multiple system atrophy seekingalpha.com - April 27 at 10:34 AM
	Alterity Therapeutics Announces Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial in the United Kingdom finance.yahoo.com - April 27 at 10:34 AM
	Alterity Therapeutics to Present at the 34th Annual Roth Conference finance.yahoo.com - March 7 at 11:36 AM
	Alterity Therapeutics Limited American Depositary Shares (ATHE) nasdaq.com - February 14 at 12:06 AM
	Alterity Therapeutics Highlights New Publications On ATH434 In Parkinson's Disease finance.yahoo.com - January 28 at 6:39 PM
	Alterity announces publication of animal study on lead asset seekingalpha.com - January 28 at 8:05 AM
	Alterity Therapeutics Announces Publication Demonstrating that ATH434 is Neuroprotective in Animal Model of Parkinsonian Disorder in the Journal of Parkinson's Disease finance.yahoo.com - January 28 at 8:05 AM
	Appendix 4C - Q2 FY22 Quarterly Cash Flow Report finance.yahoo.com - January 27 at 8:39 AM
	Pre-market Movers: KAVL, ATHE, BLI, PSTV, CNSP… markets.businessinsider.com - January 6 at 8:43 AM
	Alterity Therapeutics wins U.S. patent related to neurological diseases seekingalpha.com - January 6 at 8:43 AM
	Alterity Therapeutics Granted New US Patent for Compounds for Neurodegenerative Diseases Including Parkinson's and Alzheimer's finance.yahoo.com - January 6 at 8:43 AM
	Alterity Therapeutics to Present at the H.C. Wainwright BIOCONNECT Virtual Conference finance.yahoo.com - January 5 at 9:54 AM
	Alterity Therapeutics to Participate in Two Upcoming Investor Conferences finance.yahoo.com - November 22 at 8:31 AM
	Alterity Therapeutics Announces Presentation of ATH434 at the American Autonomic Society Virtual Meeting 2021 finance.yahoo.com - November 9 at 9:51 AM
	Alterity Therapeutics Announces New Publications Providing Further Evidence of the Potential of ATH434 to Treat Neurodegenerative Diseases finance.yahoo.com - November 4 at 8:46 AM
	Appendix 4C - Q1 FY22 Quarterly Cash Flow Report finance.yahoo.com - October 29 at 9:00 AM
	ATHE, NMTR and PXLW among pre among gainers seekingalpha.com - August 22 at 3:36 PM
	99 Biggest Movers From Yesterday msn.com - August 6 at 10:01 AM
	Thinking about buying stock in Exela Technologies, Alterity Therapeutics, Farmmi, Micron Technology, or Under Armour? marketwatch.com - August 5 at 8:18 AM
	Alterity Therapeutics Announces New US Patent to Expand its Portfolio of Compounds for Neurodegenerative Diseases including Alzheimer's and Parkinson's finance.yahoo.com - August 4 at 9:44 AM
	Appendix 4C - Q4 FY21 Quarterly Cash Flow Report finance.yahoo.com - July 30 at 1:23 PM
	Alterity Therapeutics Says Treatment With ATH434 Neuroprotective And Improved Motor Function markets.businessinsider.com - July 15 at 12:29 PM
	Pre-market Movers: ATHE, HUDI, VERB, SGOC, IMUX… markets.businessinsider.com - July 15 at 7:29 AM
	Alterity Therapeutics shares rise as its new US patent supports bid to find treatment for Alzheimer's and Parkinson's proactiveinvestors.com.au - July 1 at 6:03 PM
	Want to Buy Alterity Therapeutics (ATHE) Stock? See This First. finance.yahoo.com - July 1 at 6:03 PM
	What's Sending Alterity Therapeutics Shares Higher? benzinga.com - July 1 at 1:03 PM
	Alterity Therapeutics granted a new US patent targeting major neurodegenerative diseases including Alzheimer's and Parkinson's finance.yahoo.com - July 1 at 8:02 AM
	Alterity Therapeutics Limited Received European Union Regulatory Guidance for ATH434 Phase 2 Clinical Trial finance.yahoo.com - June 23 at 9:51 AM
	Alterity Therapeutics (ASX:ATH) Is In A Good Position To Deliver On Growth Plans finance.yahoo.com - June 7 at 7:25 PM
	Alterity Therapeutics Limited Appendix 4C - Q3 FY21 Quarterly Cash Flow Report finance.yahoo.com - April 29 at 8:47 AM
	Alterity's Stock Is Trading Higher As ATH434 Preserves Neurons, Motor Performance In Animal Model With Neurodegenerative Disorder finance.yahoo.com - April 21 at 1:22 PM
	24 Stocks Moving in Wednesday's Pre-Market Session msn.com - April 21 at 8:21 AM

Get Alterity Therapeutics News Delivered to You Automatically

This page (NASDAQ:ATHE) was last updated on 1/29/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Alterity Therapeutics - ATHE News Today

ATHE Media Mentions By Week

ATHE Media Sentiment

ATHE News Coverage

About MarketBeat

Popular Tools

Financial Calendars

Terms & Info